Expert Ratings For Insulet
Insulet (NASDAQ:PODD) underwent analysis by 7 analysts in the last quarter, revealing a spectrum of viewpoints from bullish…
What 8 Analyst Ratings Have To Say About Insulet
Within the last quarter, Insulet (NASDAQ:PODD) has observed the following analyst ratings: Bullish Somewhat Bullish Indifferent Somewhat Bearish…
10 Health Care Stocks Whale Activity In Today’s Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums…
10 Health Care Stocks Whale Activity In Today’s Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums…
What Stocks Drove The Recent Record Rally? A Breakdown You Can’t Miss
The technology sector has done well during the recent stock market rally as seen in indices such as Nasdaq 100 and S&P 500.
Barron’s Weekend Stock Picks: Chevron, Apple, Disney And Insulet’s Stock Increase
Benzinga reviews this weekend's top stories covered by Barron's. Here are the articles investors need to read.
Expedia Group, Gartner, Cloudflare, Cardinal Health And Other Big Stocks Moving Higher On Friday
U.S. stocks traded higher, with the Dow Jones gaining around 200 points on Friday. Here are some big stocks recording gains in today’s session.
Omnipod Insulin Pump Working Well For Insulet, Lifts Annual Forecast
Insulet Corporation (NASDAQ: PODD) reported Q3 sales of $432.7 million, up 27.0%, or 25.1% in constant currency, beating the
Insulet Sees Q4 Revenue Growth Of 22% To 25%; FY23 Revenue Raising Its Expected Revenue Growth To A Range Of 26% To 27%
2023 Outlook:Revenue Guidance (in constant currency):For the year ending December 31, 2023, the Company is raising its expected revenue growth to a range of 26% to 27% (previously 22% to 25%). Revenue growth ranges by
Earnings Scheduled For November 2, 2023
Companies Reporting Before The Bell
• AudioCodes (NASDAQ:AUDC) is estimated to report quarterly earnings at $0.18 per share on revenue of $61.52 million.